N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development of diabetic microvascular complications through the promotion of retinal angiogenesis and increased vascular permeability.
It was reported in the literature that NAC administration was safe in several studies. It was shown that the dose of 1200 mg is safe and effective.
To the best of our knowledge, the present study is the first to be designed to evaluate the effect of N-acetyl cysteine on diabetic retinopathy in type 2 diabetic patients.
Patients with type 2 diabetes mellitus
Patients with mild to moderate degrees of diabetic retinopathy
Patients over the age of 18 and under the age of 70 years
Patients who voluntarily give their informed consent
• Patients with any other ophthalmologic conditions than diabetic retinopathy
Patients with previous surgical or laser treatment
Pregnant or breastfeeding patients
Patients using antioxidants.
Ain Shams University
Lead sponsor
National Institute of Diabetes and Endocrinology, Egypt
Collaborator